Nonprofit to offer biosimilar insulins at low cost regardless of insurance status
Click Here to Manage Email Alerts
The nonprofit generic pharmaceutical company Civica will manufacture and distribute biosimilar versions of three widely prescribed insulins priced at $30 per vial or $55 for five pens, according to a press release from JDRF.
The price-capped biosimilar versions of glargine, lispro and aspart will be available to anyone without regard to insurance status likely beginning in 2024, according to the release.
The project undertaken by Civica is backed by a consortium of diabetes advocacy groups, health care systems, payers and philanthropies, including JDRF, Arnold Ventures, Beyond Type 1, Blue Cross Blue Shield Association and 12 independent BCBS companies, Gary and Mary West Foundation, Glen E. Tullman Fund, Intermountain Healthcare, Kaiser Permanente, Peterson Center on Healthcare, Providence, The Leona M. and Harry B. Helmsley Charitable Trust, Transcarent and Trinity Health.
“The Civica insulin development project is a tremendous step forward to make insulin accessible for all, regardless of insurance status, and address a national crisis,” Aaron Kowalski, PhD, CEO of JDRF, said in the release. “JDRF is firm in its stance that people with insulin-dependent diabetes should not have to choose between food and shelter or life-saving medicine because of its cost. This project will make a real difference for millions of Americans, including those living with type 1 diabetes, and we are proud to support it.”
Collapse
Read more about
Click Here to Manage Email Alerts